E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Add to balance / Manage account  User:  Log out
Prospect News home > News index > List of issuers A > Headlines for Allarity Therapeutics, Inc. > News item
Published on 12/21/2021 in the Prospect News PIPE Daily and Prospect News Private Placement Daily.

Allarity Therapeutics closes $20 million PIPE investment of preferred stock

Chicago, Dec. 21 – Allarity Therapeutics, Inc. closed on a $20 million PIPE investment of 20,000 shares of its preferred stock for $1,000 per share with 3i, LP, according to a press release.

The placement included a common stock purchase warrant to purchase 2,018,958 shares of common stock.

LifeSci Capital acted as exclusive placement agent for the PIPE Investment.

Cambridge, Mass.-based Allarity Therapeutics develops cancer treatment drugs.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.